Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) Equity Average (2021 - 2025)

Historic Equity Average for RxSight (RXST) over the last 5 years, with Q3 2025 value amounting to $277.0 million.

  • RxSight's Equity Average rose 27.4% to $277.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.0 million, marking a year-over-year increase of 27.4%. This contributed to the annual value of $220.8 million for FY2024, which is 7645.37% up from last year.
  • RxSight's Equity Average amounted to $277.0 million in Q3 2025, which was up 27.4% from $278.7 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Equity Average registered a high of $280.3 million during Q1 2025, and its lowest value of -$81.3 million during Q3 2021.
  • Moreover, its 5-year median value for Equity Average was $159.3 million (2023), whereas its average is $168.7 million.
  • The largest annual percentage gain for RxSight's Equity Average in the last 5 years was 22673.15% (2022), contrasted with its biggest fall of 3571.78% (2022).
  • RxSight's Equity Average (Quarter) stood at $144.6 million in 2021, then crashed by 35.72% to $92.9 million in 2022, then skyrocketed by 73.16% to $160.9 million in 2023, then soared by 73.53% to $279.2 million in 2024, then fell by 0.81% to $277.0 million in 2025.
  • Its Equity Average was $277.0 million in Q3 2025, compared to $278.7 million in Q2 2025 and $280.3 million in Q1 2025.